Giuseppe Procopio, Director of the Genitourinary Cancer Unit at National Cancer Institute Foundation, IRCCS, shared on X:
“New insights from PROpel: olaparib with abiraterone showed the greatest benefit in mCRPC with BRCA2 mutations, highlighting the importance of genomic testing to guide treatment decisions and advance precision oncology.”
Title: Efficacy of Olaparib Plus Abiraterone for Patients with Metastatic Castration-resistant Prostate Cancer and Single Homologous Recombination Repair Gene Mutations in PROpel
Authors: Neal Shorea, Noel W. Clarkeb, Andrew J. Armstrongc, Mototsugu Oyad, Giuseppe Procopioe, João Daniel Guedesf, Cagatay Arslang, Niven Mehrah, Emma Browni, Jae Young Joungj, Mikio Sugimotok, Karina Viannal, Christian Hosiusm, Alan Barniclen, Yu-zhen Liuo, Elizabeth A. Harringtonp, Douglas Longworthp, Jinyu Kangq, Fred Saad
You can also read:
PSMAddition: [177Lu]Lu-PSMA-617 Improves Radiographic PFS in PSMA-Positive mAPMN/S Prostate Cancer
